2. Academic Validation
  3. Synthesis and evaluation of indenopyrazoles as cyclin-dependent kinase inhibitors. 3. Structure activity relationships at C3(1,2)

Synthesis and evaluation of indenopyrazoles as cyclin-dependent kinase inhibitors. 3. Structure activity relationships at C3(1,2)

  • J Med Chem. 2002 Nov 21;45(24):5233-48. doi: 10.1021/jm0201722.
Eddy W Yue 1,  C Anne Higley,  Susan V DiMeo,  David J Carini,  David A Nugiel,  Carrie Benware,  Pamela A Benfield,  Catherine R Burton,  Sarah Cox,  Robert H Grafstrom,  Diane M Sharp,  Lisa M Sisk,  John F Boylan,  Jodi K Muckelbauer,  Angela M Smallwood,  Haiying Chen,  Chong-Hwan Chang,  Steven P Seitz,  George L Trainor
Affiliations

Affiliation

  • 1 Bristol-Myers Squibb Company, Experimental Station, P.O. Box 80500, Wilmington, Delaware 19880-0500, USA. eddy.yue@bms.com
PMID: 12431051 DOI: 10.1021/jm0201722
Abstract

The identification of indeno[1,2-c]pyrazol-4-ones as inhibitors of cyclin-dependent kinases (CDKs) has led to the discovery of a series of novel and potent compounds. Herein, we report the effects of substitutions at C3 of the indeno[1,2-c]pyrazol-4-one core with alkyls, heterocycles, and substituted phenyls. Substitutions at the para position of the phenyl ring at C3 were generally well-tolerated; however, larger groups were generally inactive. For alkyls directly attached to C3, longer chain substituents were not tolerated; however, shorter alkyl groups and cyclic alkyls were acceptable. In general, the heterocycles at C3 gave the most potent analogues. One such heterocycle, 24j, was examined in detail and was determined to have a biological profile consistent with CDK inhibition. An X-ray crystal structure of one of the alkyl compounds, 13q, complexed with CDK2 was determined and showed the inhibitor residing in the adenosine 5'-triphosphate pocket of the Enzyme.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-160941
    CDK2 Inhibitor
    CDK